Radiotherapy reduces @entity4164 in XXXX .

@entity1 @entity179 @entity4164 @entity746
@entity746 ( @entity746 ) is a progressive @entity179 . @entity4164 is a frequent problem in @entity746 @entity1 with bulbar symptoms, because of progressive weakness of oral, lingual and pharyngeal muscles. This prospective study aimed to investigate the putative effect of palliative single-dose radiotherapy on problematic @entity4164 in @entity1 with @entity746 . Twenty @entity1 with @entity746 and problematic drooling were included; 14 were given radiotherapy with a single fraction of 7.5 Grey (Gy). Five @entity1 were treated with botulinum toxin A (BTX-A) injections (20 U) into the parotid glands; two of these were later given radiotherapy. Symptom assessment, clinical examination and measurements of salivary flow (ml/min) were performed before and after treatment (1-2 weeks, 3 months). Salivary secretion was significantly reduced after radiation treatment, with a mean reduction of 60% (1 week) and 51% (2 weeks). Three months post-treatment, 21% reduction of the salivary secretion was observed compared with salivation before treatment. Mean salivary flow was not reduced after BTX-A treatment in five @entity1 . No serious side-effects were observed with either of the two treatment modalities. Single-dose radiotherapy (7.5 Gy) significantly reduces @entity4164 and is an effective and safe palliative treatment in @entity1 with @entity746 .
